BioNexus Gene Lab Corp BGLC 深 滬
已收盤 04-02 16:00:00 美东时间
2.2083
-0.062
-2.72%
華盛通- 最 高2.27
- 今 開2.27
- 成交量 1659股
- 最 低 2.1869
- 昨 收 2.27
- 總市值 522.01万
- 52周最高 15.60
- 市盈率 靜 --
- 換手率 0.07%
- 52周最低 1.92
- 委 比 0.50%
- 總股本 236.38万
- 歷史最高 94.90
- 量 比 0.52
- 振 幅 3.66%
- 歷史最低 1.92
- 每 手 1
- 風險率 1.38%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of the VitaGuard™ MRD Platform
BioNexus Gene Lab Corp. (BGLC) has appointed Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics, which focuses on advanced oncology testing and MRD liquid biopsy technologies. Fidelion commercializes the VitaGuard™ MRD technology globally, while BGLC has exclusive rights in Southeast Asia. Dr. Meyyappan, with over 15 years of experience in oncology diagnostics, will lead global commercial strategies. BGLC and Fidelion are adv...
03-11 12:45
BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman
BioNexus Gene Lab Corp. announced the restructuring of its subsidiary Chemrex Corporation Sdn. Bhd.'s board, streamlining it to two directors: Matthew L. Barsing as Chairman and Angeline Chong as Chief Financial Officer and Director. This restructuring aims to align Chemrex's governance with BioNexus's capital allocation and strategic evaluation frameworks. Chemrex remains a wholly owned subsidiary and continues to operate under BioNexus's oversi...
02-23 13:30
BioNexus Gene Lab Commences Its 2026 Deployment Phase For VitaGuard Minimal Residual Disease Platform
BioNexus Gene Lab Corp. (Nasdaq: BGLC) ("BioNexus" or the "Company"), a technology-driven precision diagnostics company, today announced the formal commencement of its 2026 Deployment Phase for the VitaGuard™
01-28 22:01
BioNexus Launches Regional Deployment of VitaGuard™ MRD Infrastructure; Positioned to Challenge Legacy Oncology Platforms Across ASEAN’s Multi-Billion Dollar Market
BioNexus Gene Lab Corp (BGLC) announced the commencement of its 2026 Deployment Phase for the VitaGuard™ Minimal Residual Disease (MRD) platform, aiming to make cancer monitoring more accessible and affordable across Southeast Asia. The platform is designed to disrupt high-cost legacy systems by targeting a cost profile below $3,000 per test. BGLC CEO Sam Tan emphasized the company's focus on regional strength and sustainable market capture, leve...
01-28 14:00
BRIEF-BioNexus Gene Lab Corp - Matthew L. Barsing Appointed As Chairman Of Chemrex Board - SEC Filing
Dec 23 (Reuters) - BioNexus Gene Lab Corp BGLC.O: BIONEXUS GENE LAB CORP - MATTHEW L. BARSING APPOINTED AS CHAIRMAN OF CHEMREX BOARD - SEC FILING Source text: [ID:n0001477932-25-009186] Further compan...
2025-12-24 06:55
BioNexus Gene Lab Executes Intellectual Property License Agreement For Southeast Asia With Fidelion Diagnostics For VitaGuard Minimal Residual Disease Liquid Biopsy Platform
BioNexus Gene Lab Corp. ("BGLC") today announced that it has executed an Exclusive Intellectual Property License Agreement for Southeast Asia with Fidelion Diagnostics Pte. Ltd. ("Fidelion") for the VitaGuard™
2025-12-01 21:07
BRIEF-Bionexus Gene Lab Corp Files For Mixed Shelf Of Up To $100 Million - SEC Filing
BioNexus Gene Lab Corp BGLC.O: BIONEXUS GENE LAB CORP FILES FOR MIXED SHELF OF UP TO $100 MILLION - SEC FILING Source text: [ID:n0001477932-25-007976] Further company coverage: BGLC.O
2025-11-08 06:15
12 Industrials Stocks Moving In Monday's Pre-Market Session
Gainers FGI Industries (NASDAQ:FGI) shares rose 35.8% to $6.46 during Monday's...
2025-10-20 20:08
BioNexus Gene Enters Partnership With BirchBioMed To Lead Birch's $10M Funding Round Through Equity Investment, Collaboration
BioNexus Gene Lab Corp (NASDAQ:BGLC, "BGLC", or the "Company")), today announced that it has entered into a non-binding Strategic Partnership Term Sheet with BirchBioMed Inc. ("Birch"), a Canadian biopharmaceutical
2025-10-20 20:01
BioNexus Gene Lab Corp Signs Strategic Partnership Term Sheet with BirchBioMed Inc.
BGLC and BirchBioMed have entered into a non-binding strategic partnership to commercialize Birch's FS2 topical platform in Southeast Asia. BGLC will lead a USD $10 million financing round for Birch and provide market and regulatory support in Malaysia and Singapore. BGLC will receive 1.5 million Birch shares in exchange for a 4.99% stake. Both companies aim to leverage their respective strengths to advance innovative skin treatments in the regio...
2025-10-20 12:00
